Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod ® 5 Automated Insulin Delivery System
Authors:
- Daniel J. DeSalvoDDDaniel J. DeSalvo
- Bruce W. BodeBBBruce W. Bode
- Gregory P. ForlenzaGFGregory P. Forlenza
- Lori M. LaffelLLLori M. Laffel
- Bruce A. BuckinghamBBBruce A. Buckingham
- Amy B. CriegoACAmy B. Criego
- Sarah A. MacLeishSMSarah A. MacLeish
- Jennifer L. SherrJSJennifer L. Sherr
- David W. HansenDHDavid W. Hansen
- Trang T. LyTLTrang T. Ly
Open Access
- 30 May 2024
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 26 (6) , 383-393
Abstract
Background: To evaluate the long-term safety and effectiveness of the Omnipod ® 5 Automated Insulin Delivery (AID) System in very young children with type 1 diabetes with up to 2 years of use. Methods: Following a 13-week single-arm, multicenter, pivotal trial that took place after 14 days of standard therapy data collection, participating children (2–5.9 years of age at study enrollment) were provided the option to continue use of the AID system in an extension phase. HbA1c was measured every 3 months, up to 15 months of total use, and continuous glucose monitor metrics were collected through the completion of the extension study (for up to 2 years). Results: Participants ( N = 80) completed 18.2 [17.4, 23.4] (median [interquartile range]) total months of AID, inclusive of the 3-month pivotal trial. During the pivotal trial, HbA1c decreased from 7.4% ± 1.0% (57 ± 10.9 mmol/mol) to 6.9% ± 0.7% (52 ± 7.7 mmol/mol, P < 0.0001) and was maintained at 7.0% ± 0.7% (53 ± 7.7 mmol/mol) after 15 months total use ( P < 0.0001 from baseline). Time in target range (70–180 mg/dL) increased from 57.2% ± 15.3% during standard therapy to 68.1% ± 9.0% during the pivotal trial ( P < 0.0001) and was maintained at 67.2% ± 9.3% during the extension phase ( P < 0.0001 from standard therapy). Participants spent a median 97.1% of time in Automated Mode during the extension phase, with one episode of severe hypoglycemia and one episode of diabetic ketoacidosis. Conclusion: This evaluation of the Omnipod 5 AID System indicates that long-term use can safely maintain improvements in glycemic outcomes with up to 2 years of use in very young children with type 1 diabetes. Clinical Trials Registration Number: NCT04476472Keywords
This publication has 14 references indexed in Scilit:
- 6. Glycemic Targets: Standards of Care in Diabetes—2023Diabetes Care, 2022
- Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical TrialDiabetes Care, 2022
- A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician RatingsJournal of Diabetes Science and Technology, 2022
- Glycemic outcomes of children 2–6 years of age with type 1 diabetes during the pediatric MiniMed ™ 670G system trialPediatric Diabetes, 2022
- Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 DiabetesNew England Journal of Medicine, 2022
- First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2021
- Parents’ experiences of caring for a young child with type 1 diabetes: a systematic review and synthesis of qualitative evidenceBMC Pediatrics, 2021
- Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal StudyDiabetes Care, 2021
- Managing diabetes in preschool childrenPediatric Diabetes, 2017
- Nighttime is the worst time: Parental fear of hypoglycemia in young children with type 1 diabetesPediatric Diabetes, 2017